<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432172</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM/2006-03</org_study_id>
    <nct_id>NCT00432172</nct_id>
  </id_info>
  <brief_title>Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients</brief_title>
  <official_title>&quot;A Randomized Multicenter Phase II Trial to Evaluate the Effectiveness of Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <brief_summary>
    <textblock>
      This is an open-label study that includes two substudies of random distribution. First,a
      sample of the primary tumor will be obtained and will be analyzed by an immunohistochemical
      technique to determine several markers.Depending on the expression of these markers, the
      patients will be characterize as group 1 (Luminal A phenotype) or group 2 (Basal phenotype)
      and a random assignment will be performed to standard or experimental treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group 1 (Luminal A):

        -  Standard treatment: EC x 4 -&gt; Tx4

        -  Selective treatment: Postmenopausic patients: exemestane x 6 months; Premenopausic
           Patients: goserelin x 6 months + exemestane x 6 months

      Group 2 (Basal):

        -  Standard treatment: EC x 4 -&gt; Tx4

        -  Selective treatment: EC x 4 -&gt; CDPT x 4
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>After surgey.</time_frame>
    <description>Pathological response (basal group): pathological response will be assessed after surgery, according to the scale of Miller &amp; Payne.
Clinical Response:
will be evaluated the clinical response to treatment according to the model established by the RECIST Group. (Response Evaluation Criteria in Solid Tumors).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1 (Luminal A) QT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 (Luminal A) HT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selective treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Basal) Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Basal) Selective treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>EC x 4 -&gt; Tx4</description>
    <arm_group_label>Group 1 (Luminal A) QT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selective treatment</intervention_name>
    <description>Postmenopausic patients: exemestane x 6 months; Premenopausic Patients: goserelin x 6 months + exemestane x 6 months</description>
    <arm_group_label>Group 1 (Luminal A) HT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>ECx4-&gt; Tx4</description>
    <arm_group_label>Group 2 (Basal) Standard treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selective treatment</intervention_name>
    <description>EC x4-&gt;CBPT x4</description>
    <arm_group_label>Group 2 (Basal) Selective treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Breast cancer with histological diagnosis.

          -  Negative HER2neu tumours(defined as IHQ 0,1+).

          -  No evidence of suspicion of metastatic disease.

          -  Age &gt;= 18 years old.

          -  Performance status (Karnofsky index) &gt;= 80 (ECOG 0,1).

          -  Adequate cardiac function by ECG in the previous 12 weeks.

          -  Hematology: neutrophils &gt;= 1,5 x10^9/l; platelets &gt;= 100 x10^9/l; hemoglobin &gt;= 10
             g/dl.

          -  Adequate hepatic function: total bilirubin &lt;= 1x upper normal limit (UNL); SGOT and
             SGPT &lt;= 2.5xUNL; alkaline phosphatase &lt;= 2.5xUNL.

          -  Adequate renal function: creatinine &lt;= 1xUNL; creatinine clearance &gt;= 60 ml/min.

          -  Patients able to comply with study treatment and follow-up.

          -  Negative pregnancy test in the previous 14 days.

        Exclusion Criteria:

          -  HER2neu positive tumours (defined as IHQ 3+ or positive FISH).

          -  Prior systemic therapy for breast cancer (immunotherapy, hormonotherapy,
             chemotherapy).

          -  Prior treatment with anthracyclines or taxanes (paclitaxel, docetaxel) for any
             previous malignancy.

          -  Prior radiotherapy for breast cancer.

          -  Bilateral invasive breast cancer.

          -  Pregnant or lactating women.

          -  Previous grade &gt;= 2 motor or sensorial neurotoxicity (National Cancer Institute Common
             Toxicity Criteria [NCI CTC]).

          -  Other serious comorbidities: congestive heart failure or unstable angina; prior
             history of myocardial infarction in previous year; uncontrolled hypertension (HT);
             high risk arrhythmias; history of significant neurological or psychiatric disorders;
             uncontrolled active infection; active peptic ulcer; unstable diabetes mellitus;
             dyspnea at rest; or chronic therapy with oxygen.

          -  Previous or current history of neoplasms different from breast cancer, except for skin
             carcinoma, cervical in situ carcinoma, or any other tumor curatively treated and
             without recurrence in the last 10 years; ductal in situ carcinoma in the same breast;
             lobular in situ carcinoma.

          -  Chronic treatment with corticosteroids.

          -  Contraindications for administration of corticosteroids.

          -  Concomitant treatment with other therapy for cancer.

          -  Males.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Antón, MD., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Spanish Breast Cancer Research Group (GEICAM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Breast Cancer Research Group (GEICAM)</name>
      <address>
        <city>San Sebastián de los Reyes</city>
        <state>Madrid</state>
        <zip>28703</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Click here for more information about this study: GEICAM 2006-03</description>
  </link>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2007</study_first_submitted>
  <study_first_submitted_qc>February 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2007</study_first_posted>
  <last_update_submitted>November 21, 2012</last_update_submitted>
  <last_update_submitted_qc>November 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Her2neu negative breast cancer.</keyword>
  <keyword>Neoadjuvant treatment.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

